1. An Liquid Chromatography–Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum
- Author
-
Tae Hatsuyama, Takaki Toda, Azusa Wakamoto, Yuji Mukai, Hideki Sato, Tatsunari Yoshida, Akihisa Fujita, and Nobuo Inotsume
- Subjects
Alectinib ,Lung Neoplasms ,Afatinib ,Carbazoles ,Erlotinib Hydrochloride ,chemistry.chemical_compound ,Crizotinib ,Piperidines ,Tandem Mass Spectrometry ,medicine ,Humans ,Anaplastic lymphoma kinase ,Pharmacology (medical) ,Osimertinib ,Sulfones ,Protein Kinase Inhibitors ,Quinazolinones ,Pharmacology ,Acrylamides ,Aniline Compounds ,Chromatography ,Ceritinib ,Gefitinib ,Dacomitinib ,Pyrimidines ,chemistry ,Erlotinib ,Chromatography, Liquid ,medicine.drug - Abstract
Background Routine therapeutic drug monitoring is a promising approach for the rational use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and anaplastic lymphoma kinase (ALK) inhibitors. The purpose of this study was to develop and validate a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous determination of five EGFR-TKIs (afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib) and three ALK inhibitors (alectinib, ceritinib, and crizotinib). Methods A 100-microliter aliquot of serum was diluted with 100 μL of 1% aqueous ammonia containing internal standards and then purified using the supported liquid extraction method. LC-MS/MS was conducted in positive ionization mode, and the method was validated according to published guidelines. Results Calibration curves were linear across concentration ranges examined. The intra- and inter-assay accuracies were 90.7-110.7% and 94.7-107.6%, respectively. All intra- and inter-assay imprecision values were ≤10.1%. The EGFR-TKIs and ALK inhibitors examined in this study, except osimertinib, which could be stored on ice for at least 5 h, were stable at room temperature for 3 h. For the internal standard-normalized matrix factors, the mean recovery and percent coefficient of variation values ranged between 54-112% and 1.7-11.7%, respectively. This method successfully determined serum concentrations of afatinib, alectinib, erlotinib, gefitinib, and osimertinib in clinical samples. Serum levels of kinase inhibitors consistently reflected those reported in previous studies. Conclusions An LC-MS/MS method suitable for the simultaneous determination of five EGFR-TKIs and three ALK inhibitors in serum was developed and validated. The newly developed method enabled the determination of five of eight target drugs examined in clinical samples. However, a large number of clinical samples need to be analyzed to verify the usefulness of the method.
- Published
- 2021
- Full Text
- View/download PDF